WNTresearch - WNT research

WNT research

WntResearch
Pipeline
Investor
NEWS
- Press Releases
- Subscribe
Corporate Governance
Contact

WntResearch increases resources for out-licensing Foxy-5

WNTresearch → Blog Large Image → Uncategorized → WntResearch increases resources for out-licensing Foxy-5

08

Aug

Date August 8, 2019

Categories Uncategorized

WntResearch increases resources for out-licensing Foxy-5

Author Marie Rave

Search

Search for:

Categories

Emission 2
Uncategorized 12
VD Brev 1

Recent Posts

Extraordinary General Meeting on Wednesday, March 10February 5, 2021
BioStock publishes interview with acting CEO!October 27, 2020
Anders Rabbe is appointed acting CEOOctober 1, 2020
BioStock publishes interview with CEO Peter MorsingSeptember 24, 2020
BioStock publishes summer interview with CEO Peter MorsingJuly 9, 2020

Archives

February 2021
October 2020
September 2020
July 2020
April 2020
October 2019
August 2019
April 2019
March 2019

A new approach to fight tumour spread!
Foxy-5 is a unique drug candidate:
Significant medical need, first-in-class, unique mode of action, excellent pharmacokinetics, strong preclinical efficacy data, favourable safety profile

QUICK LINKS

Phase 2 study
Press Releases
shares

Copyright © All rights reserved.